Literature DB >> 28414460

Analysis of Novel Interactions between Components of the Selenocysteine Biosynthesis Pathway, SEPHS1, SEPHS2, SEPSECS, and SECp43.

Flore Oudouhou1, Bastien Casu1, Arnold Steve Dopgwa Puemi1, Jurgen Sygusch1, Christian Baron1.   

Abstract

In mammalian cells, the incorporation of the 21st amino acid, selenocysteine, into proteins is guided by the Sec machinery. The function of this protein complex requires several protein-protein and protein-RNA interactions, leading to the incorporation of selenocysteine at UGA codons. It is guided by stem-loop structures localized in the 3' untranslated regions of the selenoprotein-encoding genes. Here, we conducted a global analysis of interactions between the Sec biosynthesis and incorporation components using a bioluminescence resonance energy transfer assay in mammalian cells that showed that selenocysteine synthase (SEPSECS), SECp43, and selenophosphate synthetases SEPHS1 and SEPHS2 form oligomers in eukaryotic cells. We also showed that SEPHS2 interacts with SEPSECS and SEPHS1; these interactions were confirmed by co-immunoprecipitation. To further analyze the interactions of SECp43, the protein was expressed in Escherichia coli, and small-angle X-ray scattering analysis revealed that it is a globular protein comprising two RNA-binding domains. Using phage display, we identified potential interaction sites and highlighted two residues (K166 and P167) required for its dimerization. The SECp43 structural model presented here constitutes the basis of future exploration of the protein-protein interactions among early components of the selenocysteine biosynthesis and incorporation pathway.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28414460     DOI: 10.1021/acs.biochem.6b01116

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  6 in total

1.  Identification of a peptide antagonist of the FGF1-FGFR1 signaling axis by phage display selection.

Authors:  Magdalena Lipok; Anna Szlachcic; Kinga Kindela; Aleksandra Czyrek; Jacek Otlewski
Journal:  FEBS Open Bio       Date:  2019-04-09       Impact factor: 2.693

2.  Structural analysis of human SEPHS2 protein, a selenocysteine machinery component, over-expressed in triple negative breast cancer.

Authors:  Carmine Nunziata; Andrea Polo; Angela Sorice; Francesca Capone; Marina Accardo; Eliana Guerriero; Federica Zito Marino; Michele Orditura; Alfredo Budillon; Susan Costantini
Journal:  Sci Rep       Date:  2019-11-06       Impact factor: 4.379

3.  Selenophosphate synthetase 1 deficiency exacerbates osteoarthritis by dysregulating redox homeostasis.

Authors:  Donghyun Kang; Jeeyeon Lee; Jisu Jung; Bradley A Carlson; Moon Jong Chang; Chong Bum Chang; Seung-Baik Kang; Byung Cheon Lee; Vadim N Gladyshev; Dolph L Hatfield; Byeong Jae Lee; Jin-Hong Kim
Journal:  Nat Commun       Date:  2022-02-09       Impact factor: 14.919

4.  Regulation of A-to-I RNA editing and stop codon recoding to control selenoprotein expression during skeletal myogenesis.

Authors:  Yuta Noda; Shunpei Okada; Tsutomu Suzuki
Journal:  Nat Commun       Date:  2022-05-06       Impact factor: 17.694

5.  Trypanosomatid selenophosphate synthetase structure, function and interaction with selenocysteine lyase.

Authors:  Marco Túlio Alves da Silva; Ivan Rosa E Silva; Lívia Maria Faim; Natália Karla Bellini; Murilo Leão Pereira; Ana Laura Lima; Teresa Cristina Leandro de Jesus; Fernanda Cristina Costa; Tatiana Faria Watanabe; Humberto D'Muniz Pereira; Sandro Roberto Valentini; Cleslei Fernando Zanelli; Júlio Cesar Borges; Marcio Vinicius Bertacine Dias; Júlia Pinheiro Chagas da Cunha; Bidyottam Mittra; Norma W Andrews; Otavio Henrique Thiemann
Journal:  PLoS Negl Trop Dis       Date:  2020-10-05

6.  Toenail selenium, genetic variation in selenoenzymes and risk and outcome in glioma.

Authors:  Noah C Peeri; Jordan H Creed; Gabriella M Anic; Reid C Thompson; Jeffrey J Olson; Renato V LaRocca; Sajeel A Chowdhary; John D Brockman; Travis A Gerke; L Burton Nabors; Kathleen M Egan
Journal:  Cancer Epidemiol       Date:  2018-05-25       Impact factor: 2.984

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.